NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant
Adaptive Trial Skips Monotherapy Arm, Uses Factorial Design
Eli Lilly’s drug is one of many anti-inflammatory medicines in late-stage trials against coronavirus but will be the first to be combined with Gilead’s recently approved remdesivir.
